{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T03:55:15Z","timestamp":1762660515594,"version":"build-2065373602"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100013826","name":"Candys Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Fonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.bone.2024.117053","type":"journal-article","created":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T12:30:54Z","timestamp":1708518654000},"page":"117053","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Cancer risk in patients treated with denosumab compared with alendronate: A population-based cohort study"],"prefix":"10.1016","volume":"182","author":[{"given":"Sam Kafai","family":"Yahyavi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rune","family":"Holt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadia Krarup","family":"Knudsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine Hjorth","family":"Andreassen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoffer","family":"Sejling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Meddis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susanne K.","family":"Kjaer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Schwarz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jens-Erik Beck","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Torp-Pedersen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anders","family":"Juul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Selmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Blomberg Jensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bone.2024.117053_bb0005","series-title":"Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis","first-page":"756","volume":"361(8)","author":"Cummings","year":"2009"},{"issue":"6","key":"10.1016\/j.bone.2024.117053_bb0010","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1634\/theoncologist.5-6-463","article-title":"Management of Bone Metastases","volume":"5","author":"Coleman","year":"2000","journal-title":"Oncologist"},{"issue":"2","key":"10.1016\/j.bone.2024.117053_bb0015","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s00198-010-1326-y","article-title":"Do RANKL inhibitors (denosumab) affect inflammation and immunity?","volume":"22","author":"Ferrari-Lacraz","year":"2010","journal-title":"Osteoporos. Int."},{"issue":"1","key":"10.1016\/j.bone.2024.117053_bb0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-021-22734-8","article-title":"RANKL regulates male reproductive function","volume":"12","author":"Blomberg Jensen","year":"2021","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.bone.2024.117053_bb0025","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s00198-020-05704-6","article-title":"Denosumab is not associated with risk of malignancy: systematic review and meta-analysis of randomized controlled trials","volume":"32","author":"Rosenberg","year":"2020","journal-title":"Osteoporos. Int."},{"issue":"3","key":"10.1016\/j.bone.2024.117053_bb0030","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1038\/s41416-022-01810-w","article-title":"RANKL regulates testicular cancer growth and Denosumab treatment has suppressive effects on GCNIS and advanced seminoma","volume":"127","author":"Andreassen","year":"2022","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bone.2024.117053_bb0035","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1210\/er.2007-0014","article-title":"Receptor activator of nuclear factor \u03baB ligand and osteoprotegerin regulation of bone remodeling in health and disease","volume":"29","author":"Kearns","year":"2008","journal-title":"Endocrine Reviews. The Endocrine Society"},{"issue":"2","key":"10.1016\/j.bone.2024.117053_bb0040","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0092-8674(00)81569-X","article-title":"Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation","volume":"93","author":"Lacey","year":"1998","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.bone.2024.117053_bb0045","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0092-8674(00)80209-3","article-title":"Osteoprotegerin: a novel secreted protein involved in the regulation of bone density","volume":"89","author":"Simonet","year":"1997","journal-title":"Cell"},{"issue":"12","key":"10.1016\/j.bone.2024.117053_bb0050","doi-asserted-by":"crossref","first-page":"5050","DOI":"10.1210\/endo.142.12.8536","article-title":"Minireview: the OPG\/RANKL\/RANK system","volume":"142","author":"Khosla","year":"2001","journal-title":"Endocrinology"},{"key":"10.1016\/j.bone.2024.117053_bb0055","doi-asserted-by":"crossref","first-page":"511","DOI":"10.3389\/fimmu.2014.00511","article-title":"Biology of the RANKL-RANK-OPG system in immunity, bone, and beyond","volume":"5","author":"Walsh","year":"2014","journal-title":"Front. Immunol."},{"issue":"6","key":"10.1016\/j.bone.2024.117053_bb0060","doi-asserted-by":"crossref","first-page":"3329","DOI":"10.1172\/JCI138278","article-title":"RANKL inhibition improves muscle strength and insulin sensitivity and restores bone mass","volume":"130","author":"Bonnet","year":"2020","journal-title":"J. Clin. Invest."},{"issue":"3","key":"10.1016\/j.bone.2024.117053_bb0065","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/nm.3084","article-title":"Blockade of receptor activator of nuclear factor-\u03baB (RANKL) signaling improves hepatic insulin resistance and prevents develop- ment of diabetes mellitus","volume":"19","author":"Kiechl","year":"2013","journal-title":"Nat. Med."},{"key":"10.1016\/j.bone.2024.117053_bb0070","first-page":"170","article-title":"RANKL signalling in female reproduction: a novel role of RANKL outside the skeleton?","volume":"90","author":"Bech","year":"2023","journal-title":"Endocr. Abstr."},{"key":"10.1016\/j.bone.2024.117053_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/S0092-8674(00)00103-3","article-title":"The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development","volume":"103","author":"Fata","year":"2000","journal-title":"Cell"},{"key":"10.1016\/j.bone.2024.117053_bb0080","doi-asserted-by":"crossref","DOI":"10.1038\/nature09387","article-title":"Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer","volume":"468","author":"Schramek","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.bone.2024.117053_bb0085","doi-asserted-by":"crossref","DOI":"10.1038\/nature09495","article-title":"RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis","volume":"468","author":"Gonzalez-Suarez","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.bone.2024.117053_bb0090","doi-asserted-by":"crossref","DOI":"10.1038\/nature09091","article-title":"Progesterone induces adult mammary stem cell expansion","volume":"465","author":"Joshi","year":"2010","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.bone.2024.117053_bb0095","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.3390\/ijms20092183","article-title":"RANK-RANKL signaling in cancer of the uterine cervix: a review","volume":"20","author":"van Dam","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bone.2024.117053_bb0100","article-title":"Bisphosphonates for the prevention and treatment of osteoporosis","volume":"351","author":"Maraka","year":"2015","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.bone.2024.117053_bb0105","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s00198-008-0560-z","article-title":"European guidance for the diagnosis and management of osteoporosis in postmenopausal women","volume":"19","author":"Kanis","year":"2008","journal-title":"Osteoporos Int."},{"key":"10.1016\/j.bone.2024.117053_bb0110","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2147\/CLEP.S91125","article-title":"The Danish national patient registry: a review of content, data quality, and research potential","volume":"7","author":"Schmidt","year":"2015","journal-title":"Clin. Epidemiol."},{"issue":"4","key":"10.1016\/j.bone.2024.117053_bb0115","first-page":"445","article-title":"The Danish prescription registries","volume":"44","author":"Gaist","year":"1997","journal-title":"Dan. Med. Bull."},{"issue":"7 Suppl","key":"10.1016\/j.bone.2024.117053_bb0120","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1177\/1403494810394717","article-title":"The Danish National Prescription Registry","volume":"39","author":"Kildemoes","year":"2011","journal-title":"Scand. J. Public Health"},{"issue":"7","key":"10.1016\/j.bone.2024.117053_bb0125","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1177\/1403494810393562","article-title":"The Danish cancer registry","volume":"39","author":"Gjerstorff","year":"2011","journal-title":"Scand. J. Public Health"},{"key":"10.1016\/j.bone.2024.117053_bb0130","unstructured":"International Standard Classification of Education. 2011."},{"issue":"1","key":"10.1016\/j.bone.2024.117053_bb0135","doi-asserted-by":"crossref","DOI":"10.1515\/1557-4679.1370","article-title":"Targeted minimum loss based estimation of causal effects of multiple time point interventions","volume":"8","author":"Van Der Laan","year":"2012","journal-title":"Int. J. Biostat."},{"issue":"1","key":"10.1016\/j.bone.2024.117053_bb0140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13063-022-06478-4","article-title":"Effect of a single-dose denosumab on semen quality in infertile men (the FITMI study): study protocol for a randomized controlled trial","volume":"23","author":"Yahyavi","year":"2022","journal-title":"Trials"},{"issue":"2","key":"10.1016\/j.bone.2024.117053_bb0145","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1359\/jbmr.081112","article-title":"Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine\/human) RANKL*","volume":"24","author":"Kostenuik","year":"2009","journal-title":"J. Bone Miner. Res."},{"issue":"1","key":"10.1016\/j.bone.2024.117053_bb0150","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-018-05244-y","article-title":"Soluble RANKL contributes to osteoclast formation in adult mice but not ovariectomy-induced bone loss","volume":"9","author":"Xiong","year":"2018","journal-title":"Nat. Commun."},{"issue":"8","key":"10.1016\/j.bone.2024.117053_bb0155","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1007\/s11606-021-06938-8","article-title":"Secular trends in the pharmacologic treatment of osteoporosis and malignancy-related bone disease from 2009 to 2020","volume":"37","author":"Cromer","year":"2021","journal-title":"J. Gen. Intern. Med."},{"key":"10.1016\/j.bone.2024.117053_bb0160","doi-asserted-by":"crossref","first-page":"119","DOI":"10.2147\/CIA.S14565","article-title":"Clinical utility of denosumab for treatment of bone loss in men and women","author":"Adler","year":"2011","journal-title":"Clin. Interv. Aging"},{"key":"10.1016\/j.bone.2024.117053_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbo.2019.100252","article-title":"Denosumab for bone health in prostate and breast cancer patients receiving endocrine therapy? A systematic review and a meta-analysis of randomized trials","volume":"18","author":"Galvano","year":"2019","journal-title":"J. Bone Oncol."},{"issue":"4","key":"10.1016\/j.bone.2024.117053_bb0170","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20160150","article-title":"RANK\u2013RANKL signalling in cancer","volume":"36","author":"Renema","year":"2016","journal-title":"Biosci. Rep."},{"issue":"12","key":"10.1016\/j.bone.2024.117053_bb0175","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200162","article-title":"Long-term outcomes of adjuvant denosumab in breast cancer","volume":"1","author":"Gnant","year":"2022","journal-title":"NEJM Evidence"},{"issue":"3","key":"10.1016\/j.bone.2024.117053_bb0180","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S1470-2045(18)30862-3","article-title":"Adjuvant denosumab in postmeno- pausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"20","author":"Gnant","year":"2019","journal-title":"Lancet Oncol."},{"issue":"11","key":"10.1016\/j.bone.2024.117053_bb0185","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1038\/s41416-018-0225-4","article-title":"Denosumab and breast cancer risk in postmenopausal women: a population-based cohort study","volume":"119","author":"Giannakeas","year":"2018","journal-title":"Br. J. Cancer"},{"issue":"11","key":"10.1016\/j.bone.2024.117053_bb0190","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1080\/14712598.2020.1790522","article-title":"Repurposing denosumab in lung cancer beyond counteracting the skeletal related events: an intriguing perspective","volume":"20","author":"Deligiorgi","year":"2020","journal-title":"Expert. Opin. Biol. Ther."},{"issue":"10","key":"10.1016\/j.bone.2024.117053_bb0195","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1002\/pds.4302","article-title":"Bisphosphonate use and the risk of breast cancer: a meta-analysis of observational studies","volume":"26","author":"Ou","year":"2017","journal-title":"Pharmacoepidemiol. Drug Saf."},{"issue":"9","key":"10.1016\/j.bone.2024.117053_bb0200","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1002\/jbmr.1645","article-title":"Oral alendronate use and risk of cancer in postmenopausal women with osteoporosis: a nationwide study","volume":"27","author":"Chiang","year":"2012","journal-title":"J. Bone Miner. Res."},{"issue":"2","key":"10.1016\/j.bone.2024.117053_bb0205","article-title":"Identification of patients with incident cancers using administrative registry data","volume":"61","author":"Larsen","year":"2014","journal-title":"Dan. Med. J."},{"issue":"7_suppl","key":"10.1016\/j.bone.2024.117053_bb0210","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1177\/1403494811401482","article-title":"The Danish National Patient Register","volume":"39","author":"Lynge","year":"2011","journal-title":"Scand. J. Public Health"},{"issue":"6","key":"10.1016\/j.bone.2024.117053_bb0215","first-page":"722","article-title":"Quality of ICD-10 colorectal cancer diagnosis codes in the Danish National Registry of patients","volume":"21","author":"Helqvist","year":"2012","journal-title":"Eur. J. Cancer Care (Engl)."},{"issue":"6","key":"10.1016\/j.bone.2024.117053_bb0220","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1097\/CEJ.0b013e328351c680","article-title":"Quality of urological cancer diagnoses in the Danish National Registry of patients","volume":"21","author":"Gammelager","year":"2012","journal-title":"Eur. J. Cancer Prev."}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328224000425?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328224000425?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T03:47:09Z","timestamp":1762660029000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328224000425"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":44,"alternative-id":["S8756328224000425"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2024.117053","relation":{},"ISSN":["8756-3282"],"issn-type":[{"type":"print","value":"8756-3282"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cancer risk in patients treated with denosumab compared with alendronate: A population-based cohort study","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2024.117053","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"117053"}}